Complement-Mediated Mechanisms in Anti-Gd2 Monoclonal Antibody Therapy of Murine Metastatic Cancer

Cancer Research - United States
doi 10.1158/0008-5472.can-05-1894
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Humanizing Murine IgG3 Anti-Gd2 Antibody M3F8 Substantially Improves Antibody-Dependent Cell-Mediated Cytotoxicity While Retaining Targeting in Vivo

OncoImmunology
OncologyAllergyImmunology
2012English

Ocular Abnormalities in Patients Treated With a Novel Anti-Gd2 Monoclonal Antibody, Hu14.18K322A

Journal of AAPOS
Child HealthOphthalmologyPediatricsPerinatology
2015English

Phase I Trial of Anti-Gd2 Monoclonal Antibody Hu3F8 Plus GM-CSF: Impact of Body Weight, Immunogenicity and Anti-Gd2 Response on Pharmacokinetics and Survival

OncoImmunology
OncologyAllergyImmunology
2017English

Anti-Il-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models

PLoS ONE
Multidisciplinary
2015English

Humanization and Characterization of an Anti-Human TNF-α Murine Monoclonal Antibody

PLoS ONE
Multidisciplinary
2011English

Monoclonal Antibody Therapy

AAOHN Journal
1987English

A Monoclonal Antibody to O-Acetyl-Gd2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity Without Peripheral Nervous System Cross-Reactivity

PLoS ONE
Multidisciplinary
2011English

Triple Combination Immunotherapy With GVAX, Anti-Pd-1 Monoclonal Antibody, and Agonist Anti-Ox40 Monoclonal Antibody Is Highly Effective Against Murine Intracranial Glioma

OncoImmunology
OncologyAllergyImmunology
2019English

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients With Advanced and/or Metastatic Cancer

Clinical Pharmacokinetics
Pharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy